An overview of 48 elderly-specific clinical trials of systemic chemotherapy for advanced non-small cell lung cancer

Lung Cancer

Volumn 46, Issue 1, 2004, Pages 61-76

  Hotta, Katsuyuki ^a   Ueoka, Hiroshi ^a   Kiura, Katsuyuki ^a   Tabata, Masahiro ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Calendar age; Chemotherapy; Clinical trial; Elderly patient; Non small cell lung cancer; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXIFLURIDINE; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; LONIDAMINE; MITOMYCIN; NAVELBINE; NEDAPLATIN; PACLITAXEL; VINDESINE;

AGE DISTRIBUTION; AGED; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; ELDERLY CARE; FEMALE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDLINE; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STATISTICAL ANALYSIS;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; ELIGIBILITY DETERMINATION; HEALTH STATUS; HUMANS; LUNG NEOPLASMS; TERMINOLOGY;

EID: 4444249171     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.02.018     Document Type: Review

References (88)

1. Vercelli M., Quaglia A., Casella C., Parodi S., Micheli A., Capocaccia R. Cancer in elderly: the population-based indexes in Europe (incidence, mortality, survival and prevalence). Ann. Oncol. 9(Supppl 3):1998;55-56
2. Yancik R. Cancer burden in the aged. An epidemiologic and demographic overview. Cancer. 80:1997;1273-1283
3. Lee-Chiong T.L. Jr., Matthay R.A. Lung cancer in the elderly patient. Clin. Chest. Med. 14:1993;453-478
4. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
5. Earle C.C., Tsai J.S., Gelber R.D., Weinstein M.C., Neumann P.J., Weeks J.C. Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J. Clin. Oncol. 19:2001;1064-1070
6. Hutchins L.F., Unger J.M., Crowley J.J., Coltman C.A., Albain K.S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341:1999;2061-2067
7. Hillner B.E., McDonald M.K., Desch C.E., Smith T.J., Penberthy L.T., Retchin S.M. A comparison of patterns of care of nonsmall cell lung carcinoma patients in a younger and Medigap commercially insured cohort. Cancer. 83:1998;1930-1937
8. Hotta K., Sekine I., Tamura T., Sawada M., Watanabe H., Kusaba H., et al. A phase I/II study of cisplatin and vinorelbine chemotherapy in patients with advanced non-small cell lung cancer. Jpn. J. Clin. Oncol. 31:2001;596-600
9. Fukuda M., Takatani H., Nagashima S., Fukuda M., Kinoshita A., Narasaki F., et al. A phase I study of vinorelbine and carboplatin in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;236b. [abstract 2763]
10. Leong S.S., Foo K.F., Tay M.H., Toh C.K., Lim D., See H.T., et al. A randomized phase II trial of gemcitabine, vonorelbine or docetaxel in the treatment of elderly and/or poor performance state patients with non-small cell lung cancer (NSCLC). Lung Cancer. 41(Suppl 2):2003;S18. [abstract O-53]
11. Harper H., Marsland T., Mitchell P., Infortuno J., Bolton M.G. Phase II study of first line chemotherapy using CT-2103 in patients with non-small cell lung cancer who are >70 years of age or who have PS = 2. Proc. Am. Soc. Clin. Oncol. 21:2002;217b. [abstract 2685]
12. Bodkin D., Neubauer M., Bolton M.G. Phase 2 study of first line chemotherapy using CT-2103 (XYOTAX™) in patients with non-small cell lung cancer who are = 70 years of age or performance status (PS) = 2. Lung Cancer. 41(Suppl 2):2003;S43. [abstract O-140]
13. Buccheri G., Ferrigno D. Front-line weekly chemotherapy with gemcitabine for unfit and/or elderly patients with non-small cell lung cancer (NSCLC). Lung Cancer. 41(Suppl 2):2003;S228. [abstract P-540]
14. Comella G., Comella P., De Cataldis G., Gaizo F.D., Lorusso V., Panza N., et al. Gemcitabine plus vinorelbine (GV) or paclitaxel (GT) vs gemcitabine (G) or paclitaxel (T) alone in elderly or unfit non-small cell lung cancer (NSCLC) patients. SICOG 9909 Phase III Trial. Proc. Am. Soc. Clin. Oncol. 22:2003;629. [abstract 2529]
15. Portalone L., Antilli A., Brocchieri P.L., Lombardi A., Nunziati F., Pezzuto A., et al. A phase II trial with gemcitabine (G) and vinorelbine (V) as first-line treatment in elderly and poor performance status non small cell lung cancer (NSCLC) patients. Proc. Am. Soc. Clin. Oncol. 22:2003;671. [abstract 2699]
16. Ferrau F., Priolo D., Antonelli G., Cali' S., Colina P., Mattina M., et al. Sequential vinorelbine (VNB) and gemcitabine (Gem) administration in elderly or unfit patients (pts) affected by advanced non small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 22:2003;676. [abstract 2719]
17. Shehadeh N.J., Kalemkerian G.P., Wozniak A., Kraut M., Belzer K., Ward D., et al. Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly ( 70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;686. [abstract 2758]
18. Hainsworth J.D., Erland J.B., Barton J.H., Thompson D.S., Stagg M.P., Bradof J.E., et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clin. Lung Cancer. 5:2003;33-38
19. Beretta G.D., Michetti G., Belometti M.O., Gritti G., Quadri A., Poletti P., et al. Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer. Br. J. Cancer. 83:2000;573-576
20. Choi I.S., Kim B.S., Park S.R., Lee S.Y., Kim do Y., Kim J.H., et al. Efficacy of modified regimen with attenuated doses of paclitaxel plus carboplatin combination chemotherapy in elderly and/or weak patients with advanced non-small cell lung cancer. Lung Cancer. 39:2003;99-101
21. Hainsworth J.D., Burris H.A. III, Litchy S., Morrissey L.H., Barton J.H., Bradof J.E., et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung cancer. Cancer. 89:2000;328-333
22. Feliu J., Gomez L.L., Madronal C., Espinosa E., Espinosa J., Giron C.G., et al. Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Cancer. 86:1999;1463-1469
23. West W.H., Birch R., Sysel I.A., Schell F.M., Liebmann J., Tongol J., et al. A phase II trial of weekly paclitaxel in elderly patients or those with decreased performance status with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;258b. [abstract 2782]
24. Tsuchiya S., Takei Y., Watanabe S., Hoshino H., Kaira K., Kawamura Y., et al. Phase I study of biweekly paclitaxel P and carboplatin C for elderly or high risk patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 21:2002;228b. [abstract 2731]
25. Manno P., Santo A., Azzoni P., Zuliani S., Pedersini R., Oliani C., et al. Unresectable non-small cell lung cancer (NSCLC) in elderly or poor performance patients treated with gemcitabine (GEM) and vindesine (VDS): an effective and well tolerated regimen. Proc. Am. Soc. Clin. Oncol. 20:2001;270b. [abstract 2832]
26. Garbo L., Marsland T., Garfield D., Khan M., Asmar L. A phase II study of weekly paclitaxel (Taxol) in stage IIIB, IV, or relapsed after local therapy, non-small cell lung cancer (NSCLC) patients with a performance status of 2 and/or >70 years (yrs) of age, with (paraplatin) administered at disease progression. Proc. Am. Soc. Clin. Oncol. 20:2001;267b. [abstract 2821]
27. Frasci G., Comella P., Panza N., De Cataldis G., Del Gaizo F., Pozzo C., et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Eur. J. Cancer. 34:1998;1710-1714
28. Edelman M.J., Gandara D.R., Lau D., Lara P., Lauder I. Sequential chemotherapy with carboplatin (C) and gemcitabine (G) followed by paclitaxel (P) in poor performance status (PS) and elderly patients (pts) with non-small cell lung cancer (NSCLC). Lung Cancer. 29(Suppl 1):2000;16. [abstract 49]
29. Mattioli R., Morese R., Imperatori L., Laici G., Gattafoni P., Lippe P. Weekly cisplatin (P) and vinorelbine (V) is active, manageable and provides clinical benefit in advanced non-small cell lung cancer (ANSCLC) elderly or poor performance status (PS) patients. Ann. Oncol. 13(Suppl 5):2002;104
30. Oshita F., Kurata T., Kasai T., Fakuda M., Yamamoto N., Ohe Y., et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn. J. Cancer Res. 86:1995;1198-1202
31. Ando M., Minami H., Ando Y., Sakai S., Shimono Y., Sugiura S., et al. Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin. Cancer Res. 5:1999;1690-1695
32. Lichtman S.M., Buchholt Z.M., Marino J., Schulman P., Allen S.L., Weiselberg L., et al. Use of cisplatin for elderly patients. Age Aging. 21:1992;202-204
33. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
34. Frasci G., Lorusso V., Panza N., Comella P., Nicolella G., Bianco A., et al. Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small cell lung cancer. J. Clin. Oncol. 18:2000;2529-2536
35. Gridelli C., Perrone F., Gallo C., Cigolari S., Rossi A., Piantedosi F., et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J. Natl. Cancer Inst. 95:2003;362-372
36. De Marinis F., Rinaldi M., Ardizzoni A., Bruzzi P., Pennucci M.C., Portalone L., et al. The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): a phase III randomized FONICAP trial. Tumori. 85:1999;177-182
37. Colleoni M., Gaion F., Nelli P., Mario Colmellere G., Manente P. Weekly vinorelbine in elderly patients with non-small cell lung cancer. Tumori. 80:1994;448-452
38. Veronesi A., Crivellari D., Magri M.D., Cartei G., Mansutti M., Foladore S., et al. Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur. J. Cancer. 32:1996;1809-1811
39. Tononi A., Panzini I., Oliverio G., Pasquini E., Gianni L., Nicolini M., et al. Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients. J. Chemother. 9:1997;304-308
40. Gridelli C., Perrone F., Gallo C., De Marinis F., Ianniello G., Cigolari S., et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur. J. Cancer. 33:1997;392-397
41. Buccheri G., Ferrigno D. Vinorelbine in elderly patients with inoperable nonsmall cell lung cancer. Cancer. 88:2000;2677-2685
42. Mattioli R., Imperatori L., Casadei V., Manna G., Frausini G., Guidi F., et al. The impact of vinorelbine in elderly (aged >70 years) with NSCLC: a preliminary report. Lung Cancer. 18(Suppl 1):1997;41. [abstract 150]
43. Schulz T.K., Geyer S.M., Jatoi A., Castillo R., Fitch T.R., Dakhil S.R., et al. Oral vinorelbine in elderly patients (65 years old) with advanced non-small cell lung cancer (NSCLC): a phase II trial from the North Central Cancer Treatment Group. Proc. Am. Soc. Clin. Oncol. 22:2003;752. [abstract 3022]
44. Gridelli C., De Marinis F., Manegold C., Mali P., Portalone L., Castelnau O., et al. Results of a phase II study conducted in elderly patients with unresectable localised or metastatic non-small cell lung cancer (NSCLC) with oral vinorelbine given as a weekly monotherapy. Lung Cancer. 41(Suppl 2):2003;S44. [abstract O-144]
45. Quoix E., Breton J.L., Ducoline A., Depierre A., Lemarie E., Moro D., et al. First-line 4-weeks (4W) versus 3-weeks (3W) single agent gemcitabine (Gem) in elderly patients (pts) with NSCLC: a randomized multicentre phase II study. Proc. Am. Soc. Clin. Oncol. 22:2003;629. [abstract 2530]
46. Bianco V., Rozzi A., Tonini G., Santini D., Magnolfi E., Vincenzi B., et al. Gemcitabine as single agent chemotherapy in elderly patients with stages III-IV non-small cell lung cancer(NSCLC): a phase II study. Anticancer Res. 22:2002;3053-3056
47. Ricci S., Antonuzzo A., Galli L., Tibaldi C., Bertuccelli M., Lopes Pegna A., et al. Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer. A multicenter phase II study. Lung cancer. 27:2000;75-80
48. Altavilla G., Adamo V., Buemi B., Marabello G., Maisano R., Lupo G., et al. Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer. Anticancer Res. 20:2000;3675-3678
49. Martoni A., Di Fabio F., Guaraldi M., Piana E., Ramini R., Lelli G., et al. Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small cell lung cancer. Am. J. Clin. Oncol. 24:2001;614-617
50. Wilson J., Burkes R., Shepherd F., Spadafora S., Iglesias J. Single agent gemcitabine for elderly patients with non small cell lung cancer (NSCLC): a phase II study. Proc. Am. Soc. Clin. Oncol. 19:2000;547a. [abstract 2157]
51. Pasquini E., Tassinari D., Nicolini M., Gianni L., Arcangeli V., Polselli A., et al. Gemcitabine in advanced non small cell lung cancer (NSCLC): a valid option in geriatric patients. Lung Cancer. 24:1999;202-203
52. Yoshimura N., Kudoh S., Negoro S., Takifuji N., Nakagawa K., Fukuoka M. A phase II Study of docetaxel in elderly patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 19:2000;532a. [abstract 2093]
53. Tibaldi C., Bernardini I., Russo F., Chella A., Toma G., Tempestini F., et al. Second line chemotherapy with docetaxel in elderly advanced NSCLC patients: a phase II study. Lung Cancer. 41(Suppl 2):2003;S281. [abstract P-31]
54. Fidias P., Supko J.G., Martins R., Boral A., Carey R., Grossbard M., et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin. Cancer Res. 7:2001;3942-3949
55. Gallotti P., Chiesa E., Olgiati A., Bottaro G., Natale G., Freddi E. Vindesine as monochemotherapy in non small cell lung cancer (NSCLC) in elderly patients. Ann. Oncol. 3(Suppl 5):1992;36
56. Baldini E., Tibaldi C., Pfanner E., Ricci S., Falcone A., Ceribelli A., et al. Phase II study of oral doxifluridine in elderly patients with advanced non-small cell lung cancer. Am. J. Clin. Oncol. 19:1996;592-594
57. Martins S., Pereira J., Ikari F., Nikaedo S., Otavi G. Chemotherapy (CT) with cisplatin and vinorelbine for elderly non-small cell lung cancer (NSCLC) patients. Proc. Am. Soc. Clin. Oncol. 18:1999;468a
58. Lippe P., Imperatori L., Casadei F., Guidi F., Gattafoni P., Consales D.L., et al. Weekly W cisplatin P and vinorelbine, V in advanced non-small cell lung cancer (ANSCLC) elderly patients: a phase II study. Ann. Oncol. 11(Suppl 4):2000;73. [abstract 321PD]
59. Feliu J., Martin G., Madronal C., Rodriguez-Jaraiz A., Castro J., Rodriguez A., et al. Combination of low dose cisplatin plus gemcitabine for treatment of elderly patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 52:2003;247-252
60. Lippe P., Silva R.R., Giuliodori L., Monterubbianesi M.C., Mattioli R., Massacesi C., et al. Clinical benefit of gemcitabine-cisplatin in advanced non-small cell lung cancer elderly patients. Anticancer Res. 22:2002;1053-1060
61. Berardi R., Porfiri E., Scartozzi M., Lippe P., Silva R.R., Nacciarriti D., et al. Elderly patients with advanced non-small cell lung cancer. A phase II study with weekly cisplatin and gemcitabine. Oncology. 65:2003;198-203
62. Moscetti L., Saltarelli R., Signorelli C., Padalino D., De Marco S., Capomolla E., et al. The combination of gemcitabine and cisplatin in the general population of elderly patients with advanced NSCLC. Lung Cancer. 41(Suppl 2):2003;S96. [abstract P-23]
63. Niho S., Ohe Y., Yokoyama A., Watanabe K., Saijo N., Nishiwaki Y. A phase II study of docetaxel (D) and cisplatin (C) (DC) administered as three consecutive weekly infusions in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. 22:2003;679. [abstract 2732]
64. Kanat O., Evrensel T., Demiray M., Kurt E., Gonullu G. Cisplatin plus etoposide in advanced non-small cell lung cancer patients age of 70 years or older. Lung Cancer. 41:2003;233-234
65. Souquet P.J., Bornbaron P., Brunel-Crova J., Bernard J.P. Treatment of advanced and disseminated non small cell lung cancer (NSCLC) in elderly patients: results of the MIC regimen. Lung Cancer. 18(Suppl 1):1997;24
66. LeCaer H., Delhoume J.Y., Thomas P.A., Berard H., Paillotin D., Barriere J.R., et al. A multicenter phase II study of carboplatin/vinorelbine in advanced non-small cell lung cancer (NSCLC) in elderly patients (GFPC 9902). Proc. Am. Soc. Clin. Oncol. 22:2003;677. [abstract 2723]
67. Maestu I.C., Torregrosa D., Llorca C., Albert A., Gómez- Aldaraví L., Molins C., et al. Efficacy of carboplatin, Efficacy of carboplatin & gemcitabine in the treatment of elderly patients with advanced non small cell lung cancer (ANSCLC). Proc. Am. Soc. Clin. Oncol. 20:2001;401a. [abstract 1599]
68. Molinier O., Milleron B., Breton J.L., Depierre A., Mennecier B., Gervais R., et al. Multicenter phase II trial of carboplatin and weekly paclitaxel as first line treatment in elderly patients with non small cell lung cancer (NSCLC): preliminary results. Proc. Am. Soc. Clin. Oncol. 22:2003;693. [abstract 2786]
69. Jatoi A., Stella P.J., Hillman S., Mailliard J.A., Vanone S., Perez E.A., et al. Weekly carboplatin and paclitaxel in elderly non-small cell lung cancer patients (>65 years of age): a phase II North Central Cancer Treatment Group Study. Am. J. Clin. Oncol. 26:2003;441-447
70. Gridelli C., Rossi A., Scognamiglio F., Guida C., Fiore F., Gatani T., et al. Carboplatin plus oral etoposide in elderly patients with advanced non small cell lung cancer. A phase II study. Anticancer Res. 17:1997;4755-4758
71. Cuzzoni Q., Strada M.R., Bernardo A., Palumbo R., Bernardo G. Carboplatin plus etoposide in elderly patients with advanced non-small cell lung cancer (NSCLC): a tolerable and active outpatient regimen. Ann. Oncol. 11(Suppl 2):2000;3
72. Santomaggio C., Portalone L., De Marinis F., Coppolino S. Phase II randomised trial: gemcitabine (GEM) + vinorelbine (VNB) vs. gemcitabine + vindesine (VDS) in stage IIIB/IV - NSCLC - elderly patients (pts). Italian Association of Hospital Pneumologists (AIPO). Lung Cancer. 29(Suppl 1):2000;S86. [abstract 283]
73. Maestu I.C., Munoz J., Lorenzo G.A., Yubero A., Torregrosa D., Esquerdo G., et al. Assessment of comorbidity, simptoms and functional status in advanced non small cell lung cancer (ANSCLC) elderly patients treated with gemcitabine & vinorelbine. Lung Cancer. 41(Suppl 2):2003;S91. [abstract P-2]
74. Baron F.J., Vazquez S., Firvida J.L., Grande C., Amenedo M., Ruiz A., et al. Sequential gemcitabine and vinorelbine in elderly patients with advanced non-small cell lung cancer. Preliminary results of a Galician multicenter phase II trial. Ann. Oncol. 11(Suppl 4):2000;114. [abstract 520P]
75. Chen Y.M., Perng R.P., Chen M.C., Tsai C.M., Ming-Liu J., Whang-Peng J. A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer patients with aged 80 or older. Lung Cancer. 40:2003;221-226
76. Salvati F., Antilli A., Rita Cruciani A., Lombardi A., Mugnaini L., Nunziati F., et al. Lonidamine plus cyclophosphamide in the treatment of advanced non-small cell lung cancer in the elderly: a phase II study. Tumori. 81:1995;48-51
77. Malarme M., Marcelis L., Kains J.P., Brenez D., Feremans W., Bracops C.H.J., et al. Ifosfamide (IFO) and vindesine (VDS) therapy for non small cell lung cancer (NSCLC) in the elderly. Ann. Oncol. 3(Suppl 5):1992;36. [abstract 140]
78. Inoue A., Kunitoh H., Mori K., Nukiwa T., Fukuoka M., Saijo N. Phase I trial of weekly docetaxel in elderly patients with non-small cell lung cancer. Lung Cancer. 38:2002;205-209
79. Yamamoto N., Tamura T., Kurata T., Yamamoto N., Sekine I., Kunitoh H., et al. Phase I and pharmacokinetic (PK) study of nedaplatin: 254-S in elderly patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 19:2000;203a. [abstract 792]
80. Ohe Y., Niho S., Kakinuma R., Kubota K., Matsumoto T., Ohmatsu H., et al. Phase I studies of cisplatin and docetaxel administered by three consecutive weekly infusions for advanced non-small cell lung cancer in elderly and non-elderly patients. Jpn. J. Clin. Oncol. 31:2001;100-106
81. Simonato L., Agudo A., Ahrens W., Benhamou E., Benhamou S., Boffetta P., et al. Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int. J. Cancer. 91:2001;876-887
82. Bray F., Sankila R., Ferlay J., Parkin D.M. Estimates of cancer incidence and mortality in Europe in 1995. Eur. J. Cancer. 38:2002;99-166
83. Balducci L., Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 5:2000;224-237
84. Deppermann K.M. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer. 33(Suppl 1):2001;115-120
85. Janssen-Heijnen M.L.G., Schipper R.M., Razenberg P.P.A., Crommelin M.A., Coebergh J.W.W. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer. 21:1998;105-113
86. Yancik R., Ganz P.A., Varricchio C.G., Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J. Clin. Oncol. 19:2001;1147-1151
87. Extermann M., Overcash J., Lyman G.H., Parr J., Balducci L. Comorbid condition and functional status are independent in older cancer patients. J. Clin. Oncol. 16:1998;1582-1587
88. Perrone F., Gridelli C., Cigolari S., Bilancia D., Piantedosi F.V., Barbera S. Baseline assessment of quality of life (QOL) is a strong prognostic factor for survival of elderly patients with advanced non-small cell lung cancer (NSCLC). A secondary analysis of the MILES study. Proc. Am. Soc. Clin. Oncol. 21:2002;337b. [abstract 1346]